The honest answer about BPC-157 side effects is that the studies capable of describing them have not been done. As of 2026 there is no published, peer-reviewed randomized controlled trial of BPC-157 in humans for any indication, and the published human safety literature totals a handful of pilot studies involving fewer than 30 people. Anyone presenting a confident side-effect profile is extrapolating from rodents.
Why BPC-157 side effects cannot be stated honestly yet
Side-effect profiles come from trials — hundreds or thousands of people taking a compound under observation, with a comparison group, for long enough that uncommon problems surface. That is how we can say semaglutide causes nausea in 44.2% of people or that tirzepatide-associated pancreatitis runs under 0.4%. Those numbers exist because someone counted.
For BPC-157, nobody has counted. The preclinical literature is genuinely extensive — a 2025 literature and patent review catalogues rodent work spanning gut, tendon, nerve and vascular models (Jóźwiak et al., Pharmaceuticals 2025) — but animal safety does not transfer to humans, and the doses, routes and durations used in those studies do not map onto how people take it.
This is not a claim that BPC-157 is dangerous. It is the narrower and more useful statement that its risk profile is uncharacterised, which is a different thing from characterised-and-clean.
What the published human data does say
The most substantive human safety report to date is a 2025 pilot study of intravenous infusion. Two participants — a 58-year-old man and a 68-year-old woman — received 10 mg of BPC-157 in saline over one hour on day one and 20 mg on day two. The infusions produced no measurable effects on biomarkers of heart, liver, kidney or thyroid function, or on blood glucose, and no side effects were reported (Lee & Burgess, Altern Ther Health Med 2025).
That is a real finding and worth having. It is also two people, for two days, by a route most people are not using. It can tell you that a large intravenous dose did not immediately derange organ-function markers in two adults. It cannot tell you what happens over months of subcutaneous use, or in someone with a condition neither participant had.
What users commonly report
Outside formal trials, the effects people describe most often are local and mild: irritation, redness or soreness at the injection site. Some report nausea, headache, fatigue or lightheadedness. These are self-reported and uncontrolled — there is no placebo group, no verification of what was actually in the vial, and no systematic follow-up — so they indicate what people notice rather than what the compound causes.
The absence of alarming reports is weak evidence in both directions. Rare and delayed effects are exactly the ones informal reporting misses.
Where BPC-157 stands with the FDA
BPC-157 is not FDA-approved for any indication, and no compounded formulation of it is FDA-approved either. On 29 September 2023 the FDA placed it in category 2 of the bulk substances used in compounding — substances that raise significant safety concerns. The agency's stated reasons are specific and worth reading: possible immunogenicity by certain routes, complexity around peptide-related impurities and characterising the active ingredient, and the fact that it had no or only limited safety information for the proposed routes of administration. At the Pharmacy Compounding Advisory Committee meeting of 23–24 July 2026, the committee voted 8–6–1 to recommend BPC-157 for the 503A bulk drug substances list. That vote is advisory; rulemaking has not concluded.
We state that plainly because it is a real part of the picture and you deserve it unvarnished. A licensed provider may still prescribe BPC-157 where they judge it appropriate — that decision is between you and your doctor, and regulatory status is one input to it rather than the whole answer.
The question worth asking instead
If the side-effect profile is unknown, the practical risk shifts to something you can actually control: what is in the vial.
BPC-157 sold without a prescription is not manufactured to the standards that apply to a dispensed medication. Independent testing of consumer peptide products has repeatedly turned up wrong quantities, degraded material and contaminants. An unknown safety profile is a reason for caution; an unknown safety profile combined with an unverified product is a different order of problem.
That is the gap a prescriber and a licensed compounding pharmacy close. Through Promise, BPC-157 is prescribed only after a licensed provider reviews your request and determines it is appropriate — and it is compounded and dispensed by a licensed U.S. pharmacy, so what is in the vial is documented. Not everyone qualifies, and the provider can decline.
Who should be most cautious
Because the human data is so thin, the sensible exclusions are broad rather than evidence-derived. BPC-157 is not appropriate during pregnancy or breastfeeding. Anyone with an active or historical cancer diagnosis should raise it explicitly: BPC-157's mechanisms in animal models involve angiogenesis and tissue growth pathways, and while there is no human evidence that this promotes tumour growth, there is also none showing it does not. People taking other medications, and anyone with significant organ dysfunction, should have the conversation rather than assume.
That conversation is the point of the intake questionnaire.
What to do with all this
BPC-157 has a large preclinical literature, a persuasive mechanistic story, and almost no human safety data. Those three facts are all true at once, and holding them together is more useful than resolving them into either enthusiasm or dismissal.
If you are considering it, the two things that most reduce your risk are having a clinician who knows your history involved in the decision, and knowing that the vial came from a licensed pharmacy. For more on the compound itself, see BPC-157 peptide therapy and BPC-157 versus TB-500.